Table 4. Share of financial and economic costs by activity in the Zimbabwe human papillomavirus vaccination project, 2014–2015.
| Activity | US$ (%) |
||
|---|---|---|---|
| Financial cost | Economic cost | Net economic cost (economic–financial) | |
| Microplanning | 2 619 (1.1) | 50 306 (9.6) | 47 687 (16.3) |
| Vaccine | 162 (0.1) | 58 704 (11.3) | 58 542 (20.0) |
| Training | 53 204 (23.2) | 69 662 (13.4) | 16 458 (5.6) |
| Social mobilization, and information materials | 55 170 (24.1) | 67 568 (12.9) | 12 398 (4.2) |
| Service delivery | 40 053 (17.5) | 113 444 (21.7) | 73 391 (25.1) |
| Supervision, monitoring and evaluation | 35 166 (15.3) | 100 611 (19.3) | 65 445 (22.4) |
| Othera | 42 770 (18.7) | 61 651 (11.8) | 18 881 (6.4) |
| Cold-chain supplementation | NA | NA | NA |
| Total | 229 144 (100.0) | 521 946 (100.0) | 292 802 (100.0) |
HPV: human papillomavirus; NA: not applicable; US$: United States dollars.
a Other activity includes items relevant to introduction and recurrent cost categories that did not fit into the specific activity categories including launch of vaccination (national and district), review of monitoring tools, stakeholders meeting, report-writing meeting, HPV strategic advisory group meetings, service of nongovernmental organization vehicles, office communications and networking meeting.
Note: We collected costs in current prices from 2014, 2015 and 2016, adjusted for inflation to 2016 US$ using the Zimbabwe consumer price index.20